---
layout: default
title: Valproic Acid
parent: 僅模型預測 (L5)
nav_order: 1280
evidence_level: L5
indication_count: 10
---

# Valproic Acid
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Valproic Acid: From Epilepsy to Trigeminal Nerve Neoplasm

## One-Sentence Summary

Valproic acid is a well-established broad-spectrum antiepileptic and mood-stabilizing agent, long used for epilepsy and seizure disorders.
The TxGNN model predicts it may be effective for **Trigeminal Nerve Neoplasm**,
but currently only **0 clinical trials** and **1 tangentially related publication** support this direction.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not formally recorded in this dataset (product is currently unmarketed here); valproic acid is a well-established antiepileptic/mood-stabilizing agent used broadly for epilepsy and seizure disorders |
| Predicted New Indication | Trigeminal Nerve Neoplasm |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this dataset. Based on known pharmacology, valproic acid is a broad-spectrum agent that enhances GABAergic transmission, blocks voltage-dependent sodium and T-type calcium channels, and inhibits histone deacetylase (HDAC). Its efficacy in epilepsy and mood disorders is well established, and the HDAC-inhibitory activity has generated theoretical interest in oncology applications.

However, the link between the original indication (epilepsy) and the predicted new indication (trigeminal nerve neoplasm) is weak. The only literature retrieved for this candidate concerns Sturge-Weber syndrome, a vascular malformation disorder, which has no direct pathological relationship to trigeminal nerve tumors. The proposed mechanistic rationale — that HDAC inhibition confers antitumor potential — remains speculative and is not supported by disease-specific evidence.

Given the absence of clinical trials, absence of tumor-specific mechanistic studies, and only a single loosely related case series, this prediction should be treated as a hypothesis generated purely by the knowledge-graph model rather than an evidence-backed repurposing candidate.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [9157801](https://pubmed.ncbi.nlm.nih.gov/9157801/) | 1997 | Case series | Anales españoles de pediatría | Retrospective review of 14 Sturge-Weber syndrome cases over 25 years, evaluating clinical characteristics, disease evolution, and therapeutic response; does not address trigeminal nerve neoplasm or valproic acid's antitumor effect directly |

---

## US Market Information

Valproic acid currently has no marketing authorization on record in this dataset (market status: Not Marketed; 0 licenses).

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite a high TxGNN model score (99.97%), the supporting evidence is at the lowest tier (L5) — there are no clinical trials and only one case series that is not directly relevant to trigeminal nerve neoplasm. The proposed mechanistic link (HDAC-mediated antitumor activity) is speculative and unconfirmed for this specific tumor type.

**To proceed, the following is needed:**
- TFDA/FDA package insert warnings and contraindications (currently a blocking data gap preventing safety pre-screening)
- Confirmed mechanism of action data from DrugBank or primary literature
- Preclinical or mechanistic studies directly linking valproic acid to trigeminal nerve tumor biology
- Continued literature surveillance to identify any emerging disease-specific evidence before reconsidering this candidate
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

